person · Reporting owner

Khattar Jack A.

Disclosed activity across 3 companies

Tapewire entity: 23273
SEC CIK: 0001539937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333	Director · President, CEO	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

SUPERNUS PHARMACEUTICALS, INC.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,258,351	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 29,849 · Balance 1,270,993 Row 2 · 2026-08-12 · Tax withholding · Disposed 12,642 · Balance 1,258,351 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-08-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-12 · Exercise / conversion · Disposed 29,849 · Balance 0 F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Common StockSEC Table I · non-derivative	IndirectBy the KBT Trust	958,100	Reported balance Holding disclosure · report date 2026-08-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 958,100

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-07 transaction · row 1 1 source row Row 1 · 2025-10-07 · Other · Disposed 5,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 08, 2024 Filed Nov 12, 2024 21:11 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	125,000	$9.13	$1,141,250.00	Disclosure SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,051,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	125,000	$0.00 Strike: $9.13	$0.00	Disclosure SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016. Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	125,000	$36.68	$4,585,000.00	Disclosure SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,172 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.27 to $37.24. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
November 07, 2024 Filed Nov 8, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	125,000	$9.13	$1,141,250.00	Disclosure SEC source: 0001628280-24-046663 · wk-form4_1731100124.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,051,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	21,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	10,045	$34.90	$350,570.50	Disclosure SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,172 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	21,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-096416 · tm2423065-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document
August 27, 2024 Filed Aug 27, 2024 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	21,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-24-093484 · tm2422824-1_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
June 11, 2024 Filed Jun 13, 2024 17:00 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	19,750	$0.00 Strike: $4.11	$0.00	Disclosure SEC source: 0000950170-24-073124 · ownership.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,750 Underlying: Common Stock · 19,750 shares Expires 2034-06-11 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 11, 2025, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 07, 2024 Filed Jun 11, 2024 22:47 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantStock Option (right to buy) · Derivative	8,500	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0001062993-24-012413 · form4.xml · derivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2034-06-07 F2 · derivative.exercise_date: The option vests in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
June 07, 2024 Filed Jun 11, 2024 22:47 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantCommon Stock	8,500	$0.00	$0.00	Disclosure SEC source: 0001062993-24-012413 · form4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
February 28, 2024 Filed Feb 29, 2024 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
February 28, 2024 Filed Feb 29, 2024 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	16,788	$27.94	$469,056.72	Disclosure SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,217 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
February 28, 2024 Filed Feb 29, 2024 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-029432 · tm247055-36_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 932,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document
February 22, 2024 Filed Feb 26, 2024 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-24-027572 · tm247055-5_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
February 22, 2024 Filed Feb 26, 2024 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	322,000	$0.00 Strike: $27.94	$0.00	Disclosure SEC source: 0001104659-24-027572 · tm247055-5_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,000 Underlying: Common Stock · 322,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2025. Read SEC document
February 12, 2024 Filed Feb 22, 2024 22:28 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	16,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-026630 · tm247055-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,022,450 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 16,500 shares were transferred from the KBT Trust to the Reporting Person on February 12, 2024 without consideration and are now owned directly. Read SEC document
February 12, 2024 Filed Feb 22, 2024 22:28 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	16,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-026630 · tm247055-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897,005 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 16,500 shares were transferred from the KBT Trust to the Reporting Person on February 12, 2024 without consideration and are now owned directly. Read SEC document
December 22, 2023 Filed Dec 26, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	25,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-129241 · tm2333640-1_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. F3 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F3 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document
December 22, 2023 Filed Dec 26, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	11,958	$27.66	$330,758.28	Disclosure SEC source: 0001104659-23-129241 · tm2333640-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 880,505 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
December 22, 2023 Filed Dec 26, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-129241 · tm2333640-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 892,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. Read SEC document
December 14, 2023 Filed Dec 18, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	25,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-126933 · tm2333121-2_4seq2.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F1 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document
September 07, 2023 Filed Sep 7, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-098985 · tm2325321-2_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
September 07, 2023 Filed Sep 7, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	16,804	$32.10	$539,408.40	Disclosure SEC source: 0001104659-23-098985 · tm2325321-2_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 867,463 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document
September 07, 2023 Filed Sep 7, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-098985 · tm2325321-2_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023. Read SEC document
August 23, 2023 Filed Aug 25, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-095389 · tm2324859-2_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
June 09, 2023 Filed Jun 13, 2023 21:37 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $2.77	$0.00	Disclosure SEC source: 0001062993-23-013436 · form4.xml · derivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-06-09 F2 · derivative.exercise_date: The option vests in full on the earlier of (i) June 9, 2024 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
June 09, 2023 Filed Jun 13, 2023 21:37 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001062993-23-013436 · form4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 9, 2024 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 16:15 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	17,300	$0.00 Strike: $11.71	$0.00	Disclosure SEC source: 0000899243-23-014857 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 6, 2024, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
May 11, 2023 Filed May 12, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	31,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-059840 · tm2315575-2_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on May 3, 2022. F3 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F3 · derivative.expiration_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
May 11, 2023 Filed May 12, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	15,005	$36.47	$547,232.35	Disclosure SEC source: 0001104659-23-059840 · tm2315575-2_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 849,267 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document
May 11, 2023 Filed May 12, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	31,250	$0.00	$0.00	Disclosure SEC source: 0001104659-23-059840 · tm2315575-2_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on May 3, 2022. Read SEC document
May 04, 2023 Filed May 8, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	31,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-057229 · tm2314899-3_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires not disclosed F1 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F1 · derivative.expiration_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
March 14, 2023 Filed Apr 10, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	20,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-043634 · tm2311944-1_4seq.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021. F2 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F2 · derivative.expiration_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
March 14, 2023 Filed Apr 10, 2023 21:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-043634 · tm2311944-1_4seq.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021. Read SEC document
February 23, 2023 Filed Feb 27, 2023 22:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	280,000	$0.00 Strike: $38.60	$0.00	Disclosure SEC source: 0001104659-23-026084 · tm237737-17_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document
February 16, 2023 Filed Feb 21, 2023 22:38 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	20,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-023878 · tm237193-4_4seq1.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-04-01 F1 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
February 15, 2023 Filed Feb 16, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	8,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-022863 · tm237056-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,038,950 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 8,750 shares were transferred from the KBT Trust to the Reporting Person on February 15, 2023 without consideration and are now owned directly. Read SEC document
February 15, 2023 Filed Feb 16, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	8,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-022863 · tm237056-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,022 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 8,750 shares were transferred from the KBT Trust to the Reporting Person on February 15, 2023 without consideration and are now owned directly. Read SEC document
February 03, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	330	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,037 Underlying: Common Stock · 330 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
February 03, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	200	$42.02	$8,404.00	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,272 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.03, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
February 03, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	330	$9.56	$3,154.80	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
February 02, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	22,515	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,367 Underlying: Common Stock · 22,515 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
February 02, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	13,532	$42.06	$569,088.26	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,142 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
February 02, 2023 Filed Feb 6, 2023 22:01 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	22,515	$9.56	$215,243.40	Disclosure SEC source: 0001104659-23-011255 · tm235112-3_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	498	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-010575 · tm235112-2_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,882 Underlying: Common Stock · 498 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	300	$42.01	$12,602.01	Disclosure SEC source: 0001104659-23-010575 · tm235112-2_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,159 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.02, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	498	$9.56	$4,760.88	Disclosure SEC source: 0001104659-23-010575 · tm235112-2_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,620	$0.00 Strike: $9.56	$0.00	Disclosure SEC source: 0001104659-23-009959 · tm235112-1_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,380 Underlying: Common Stock · 1,620 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:00 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	976	$42.01	$41,002.35	Disclosure SEC source: 0001104659-23-009959 · tm235112-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,961 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.